US FDA Vaccine Approvals Set Up CDC Votes On Merck’s Capvaxive, Moderna’s mResvia

Advisory Committee on Immunization Practices expected to vote 26-28 June on use of Merck’s 21-valent pneumococcal vaccine, Moderna’s mRNA vaccine for RSV, and an expanded age range for GlaxoSmithKline’s Arexvy RSV vaccine.

Vaccine for older woman — ACIP will consider two newly approved vaccines for adults and one with an expanded indication. • Source: Shutterstock

A lively vaccine pipeline has helped to smooth and speed the transition between US Food and Drug Administration approval and the Centers for Disease Control and Prevention’s subsequent recommendations for use, with recent approvals of three vaccine applications neatly meeting the CDC’s expectations for the 26-28 June session of its Advisory Committee on Immunization Practices.

Key Takeaways

FDA approvals of Merck’s Capvaxive, Moderna’s mResvia and a new claim for GSK’s Arexvy came in time for votes at CDC vaccine committee’s 26-28 June meeting.

The FDA approvals came in the well-trod fields of pneumococcal and respiratory syncytial virus vaccines, where CDC recommendations are already...